Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Amicus Therapeutics Inc.
DescriptionATB200, a recombinant human acid alpha-glucosidase (rhGAA), administered with AT2221, a small molecule pharmacological chaperone
Molecular Target Acid alpha glucosidase (GAA)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I/II
Standard IndicationPompe's disease
Indication DetailsTreat Pompe's disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today